NEXTBIOMEDICAL Co., Ltd.
Financials
Valuation Metrics
NEXTBIOMEDICAL Co., Ltd.'s Market Cap is ₩3344B. At end of 2025 it was ₩7400B. Ranked #588 of 2,436 in KR market (top 24%), #232 of 1,649 on KOSDAQ (top 14%), #18 of 96 in Health Care Equipment & Services (top 19%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 334.40B KRW | KR#588/2,436 Sec#18/96 |
| Revenue | 16.82B KRW | KR#2,178/2,436 Sec#72/96 |
| Net Income | -36.4M KRW | KR—/2,436 Sec—/96 |
| Total Assets | 59.85B KRW | KR#2,086/2,436 Sec#69/96 |
| Net Assets | 48.94B KRW | KR#1,887/2,436 Sec#60/96 |
| Employees | 72 | KR#1,841/2,436 Sec#72/96 |
| Value | ||
| P/B | 6.83x | KR#2,292/2,436 Sec#90/96 |
| P/S | 19.88x | KR#2,332/2,436 Sec#89/96 |
| FCF Yield | -0.57% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -0.07% | KR#1,496/2,436 Sec#51/96 |
| ROA | -0.06% | KR#1,492/2,436 Sec#50/96 |
| Op. Margin | -7.39% | KR#1,922/2,436 Sec#59/96 |
| Revenue Growth | 9.22% | KR#954/2,436 Sec#45/96 |
| Earnings Growth | -107.41% | KR#1,383/2,436 Sec#47/96 |
| Financial Health | ||
| Debt Ratio | 122.31% | KR#707/2,436 Sec#34/96 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/96 |
| FCF | -1.90B KRW | KR#1,334/2,436 Sec#41/96 |
| Cash | 4.02B KRW | KR#2,074/2,436 Sec#77/96 |
| Current Ratio | 5.11x | KR#282/2,436 Sec#22/96 |
| Performance | ||
| 1Y Return | -22.01% | KR#1,325/2,436 Sec#39/96 |
| 1M Return | 2.28% | KR#662/2,436 Sec#33/96 |
| From 52W High | -60.00% | KR#1,708/2,436 Sec#59/96 |
| 1Y MDD | -66.89% | KR#1,789/2,436 Sec#61/96 |
| Trading | ||
| Volume | 42,104 shares | KR#1,453/2,436 Sec#61/96 |
| Foreign Own. | 0.64% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | -4 KRW | KR—/2,436 Sec—/96 |
| BPS | 5,965 KRW | KR#1,308/2,436 Sec#32/96 |
Company Info
Established in 2014, NEXT BIOMEDICAL is an innovative bio-solution company specially listed on the KOSDAQ market as a technology growth company in 2024. Leveraging polymer and drug delivery system technologies, the company develops products like hemostatic agents for endoscopy and vascular embolization microspheres, earning recognition for its technological prowess and innovation through FDA and CE certifications. It is pursuing the establishment of global distribution networks and sales channels by signing distribution rights agreements in the US, Europe, and Japan through partnerships with global medical device companies. NEXT BIOMEDICAL was established in 2014 and is headquartered in Yeonsu-gu, Incheon.